Acquisition Biotech International On November 15, 2013 , we acquired 100% of the outstanding equity shares of Biotech International (Biotech), a leading, privately held French orthopaedic extremities company, for approximately $55.0 million in cash and $21.0 million of our common stock, plus additional contingent consideration with an estimated fair value of $4.3 million to be paid upon the achievement of certain revenue milestones in 2014 and 2015. All Wright common stock issued in connection with the transaction is subject to a lockup period of one year. The transaction will significantly expand our direct sales channel in France and international distribution network and add Biotech s complementary extremity product portfolio to further accelerate growth opportunities in our global extremities business. The operating results from this acquisition are included in the consolidated financial statements from the acquisition date. The acquisition was recorded by allocating the costs of the assets and liabilities acquired based on their estimated fair values at the acquisition date. The excess of the cost of the acquisition over the fair value of the net assets and liabilities acquired is recorded as goodwill. The following is a summary of the estimated fair values of the assets acquired (in thousands): Cash and cash equivalents $ 252 Accounts receivable 5,400 Inventory 5,814 Prepaid and other current assets 303 Property, plant and equipment 2,573 Intangible assets 15,500 Accounts payable and accrued liabilities (2,091 ) Deferred tax liability - current (52 ) Deferred tax liability - noncurrent (3,939 ) Net assets acquired 23,760 Goodwill 56,455 Total purchase consideration $ 80,215 The above purchase price allocation is considered preliminary and is subject to revision when the valuation of intangible assets is finalized upon receipt of the final valuation report for those assets from a third party valuation expert. The goodwill is attributable to the workforce of the acquired business and strategic opportunities t